On February 17, 2026, Baker Bros. Advisors disclosed a purchase of 455,208 shares of GRAIL (NASDAQ:GRAL), an estimated $39.33 million trade based on quarterly average pricing. What happened According to a recent SEC filing dated February 17, 2026, Baker Bros. Advisors increased its position in GRAIL by 455,208 shares. The estimated transaction value, based on the average unadjusted closing price during the fourth quarter of 2025, was $39.33 million. The quarter-end value of the position rose by $82.09 mi ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) ("Exact Sciences†), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie. ...

Company Overview - Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes through its Symphony System, which is a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression [3] Recent Developments - As of February 19, 2026, all prefunded warrants issued in the October 2025 private placement have been fully exercised, resulting in approximately 972,000 shares of common stock outstanding [1] - The company has cash exercisable warrants outstanding for approximately 1.5 million shares, with a cash exercise price of $7.00 or greater per share [1] Stock Information - Recent Schedule 13G filings by investors do not reflect the 1-for-4 reverse stock split that occurred on January 29, 2026, which may lead to discrepancies in reported beneficial ownership share amounts [2]

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 47th Annual Institutional Investors Conference – Orlando, FL Presentation on March 3rd at 8:05 a.m. Eastern Time Leerink Partners Global Health Conference – Miami, FL Fireside chat on March 9th at 10:40 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by vi. ...

Core Viewpoint - 20/20 BioLabs, Inc. has launched its Class A ordinary shares on the Nasdaq Capital Market under the ticker symbol "AIDX," aiming to scale growth through AI-powered blood tests for cancer and chronic disease detection [1][6]. Financing and Growth Strategy - The company has entered a contingent financing agreement that could provide up to $40 million, with the first $5 million expected to close today [2]. - The CEO emphasized that the Nasdaq listing is a significant milestone that positions the company for substantial growth through both organic means and mergers and acquisitions [6][7]. Product Offerings - 20/20 BioLabs offers OneTest™ for Cancer, an AI-powered multi-cancer early detection blood test that analyzes tumor-associated protein biomarkers, allowing for earlier detection of multiple cancers at a lower price point than competing tests [4][11]. - The upcoming OneTest for Longevity™, expected to launch by the end of February, will track inflammatory biomarkers associated with chronic diseases, enabling consumers to make lifestyle changes to reduce disease risk [5][11]. Technological Innovation - The company's diagnostics leverage AI models built with real-world data, enhancing accuracy and clinical usefulness, and allowing for convenient home access through new blood collection devices [3][11]. - The OneTest for Cancer may be the first multi-cancer early detection test that can be self-collected at home, which is a significant advancement in the field [4]. Regulatory Environment - Recent legislation passed by Congress aims to facilitate Medicare reimbursement for multi-cancer early detection tests by 2028, which could positively impact the company's market potential [4]. Investor Relations - 20/20 BioLabs has launched an Investor Relations section on its website, providing various resources for investors, including press releases, current share prices, and SEC filings [8].

Core Insights - Biomerica, Inc. has received approval from Vietnam's Hanoi Department of Health for its EZ Detect™ colorectal disease at-home screening test, marking a significant step in the company's global expansion into Southeast Asia [1][2][11] Group 1: Product Overview - EZ Detect™ is an FDA-cleared two-minute at-home screening test designed to detect early warning signs of colorectal cancer and other colorectal diseases [2][7] - The test identifies occult blood in stool, which is a critical early indicator of colorectal diseases, including cancer [8] - The test is user-friendly, requiring no special preparation or handling of stool, and can be completed privately at home [8][9] Group 2: Market Opportunity - Colorectal cancer is a significant public health issue in Vietnam, with 16,835 new cases reported in 2022, making it the fourth most common cancer in the country [3] - The five-year survival rate for colorectal cancer in Vietnam is only 45%, compared to 91% in the United States when detected early [3][10] - The global market for colorectal cancer screening is substantial, with approximately 1.93 million new cases and over 900,000 deaths worldwide in 2022, and these figures are expected to rise significantly by 2050 [5] Group 3: Strategic Importance - The approval of EZ Detect™ represents a milestone for Biomerica's strategic entry into Southeast Asia's rapidly growing healthcare market, which has over 680 million people and increasing healthcare spending [2][11] - The company aims to work with a major healthcare distributor in Vietnam to ensure widespread availability of the product through various sales channels [1][11] - This approval serves as a template for potential expansion into other Southeast Asian markets, emphasizing the importance of accessible at-home screening tests [11]

ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial progress in advancing manufacturing readiness and technology transfer initiatives into 2026, representing a key execution milestone as the Company transitions from clinical enrollment toward data analysis, regulatory engagement, and commercialization readiness. SYMON-II Clinical trialsBluejay is ...

Core Insights - CareDx (CDNA) announced clinical validation data for AlloHeme, a blood-based monitoring test aimed at predicting relapses in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) post-allogeneic hematopoietic cell transplant (HCT) [1][4] Group 1: AlloHeme Test Details - AlloHeme utilizes next-generation sequencing and artificial intelligence to enhance sensitivity in detecting early relapse signals compared to traditional methods [2][4] - The ACROBAT clinical study demonstrated that AlloHeme achieved 85% sensitivity and 92% specificity, detecting relapses a median of 41 days earlier than standard clinical diagnosis [9][12] - The assay's performance metrics indicate a 95% negative predictive value and a 79% positive predictive value, with an area under the curve of 0.89 [11] Group 2: Commercialization and Market Strategy - CareDx plans to roll out AlloHeme in the U.S. starting with CLIA readiness in 2026, followed by commercialization in 2027 and expected payer coverage by 2028 [3][9] - The company aims to expand its Transplant+ strategy into cell therapy and hematologic oncology, addressing unmet needs in AML and MDS monitoring [3][6] - The integrated offering will combine diagnostics, digital tools, and patient support solutions tailored for the cell therapy ecosystem [4][7] Group 3: Market Performance and Growth Potential - Following the announcement, CDNA shares increased by 2.8%, with a 65.6% rise over the past six months, significantly outperforming the industry and S&P 500 [5] - The clinical validation of AlloHeme is seen as a significant growth catalyst, enhancing CareDx's position in the cell therapy and hematologic oncology markets [6][7] - The cell therapy market is projected to reach $9.13 billion by 2026, with a compound annual growth rate (CAGR) of 22.9% through 2034, driven by advancements in technology and increasing disease prevalence [14][15]

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $878 million for the fourth quarter of 2025 and $3.25 billion for the full year of 2025, both ended December 31, 2025. "In 2025 the Exact Sciences team delivered on our mission by screening more people than ever before, helping guide more personalized treatment decisions, and successfully launching three new tests. ...

Core Insights - QuidelOrtho Corporation (QDEL) reported adjusted earnings per share (EPS) of 46 cents for Q4 2025, a decrease from 63 cents year-over-year, but exceeded the Zacks Consensus Estimate by 6.9% [1] - The company registered revenues of $723.6 million in Q4 2025, reflecting a 2.2% year-over-year increase and surpassing the Zacks Consensus Estimate by 3.6% [2] Financial Performance - The GAAP loss per share for Q4 was $1.92, an improvement from a loss of $2.65 in the same quarter last year [1] - Adjusted gross profit declined 1.8% year-over-year to $325.2 million, with an adjusted gross margin contracting by 190 basis points to 44.9% [9] - Adjusted operating profit totaled $89.3 million, down 8.7% from the prior-year quarter, with an adjusted operating margin of 12.3%, a contraction of 150 basis points [10] Revenue Breakdown - Respiratory revenues were $123.3 million, down 13.9% year-over-year, while Non-Respiratory revenues increased to $600.3 million, up 6.3% [2] - Labs revenues reached $389.2 million, an 8.1% increase, while Immunohematology revenues were $141 million, up 3.4% [3][4] - Donor Screening revenues fell significantly to $11.8 million, down 40.1%, and Point of Care revenues declined to $173.1 million, down 6.4% [4] Geographical Performance - North America revenues were $390.1 million, reflecting a decline of 2.4%, while EMEA revenues increased by 9.3% to $92.7 million [6] - Revenues from China amounted to $91.7 million, up 5.5%, and Latin America revenues increased by 22% to $73.2 million [8] Future Guidance - For 2026, QuidelOrtho expects total revenues to be in the range of $2.7 billion to $2.9 billion, with a consensus estimate of $2.71 billion [12] - The company anticipates steady growth in its core Labs business and low-single-digit growth in Immunohematology, while Point-of-Care revenues are expected to remain flat [13][14]